However, our data demonstrate a previously unappreciated mechanism by which IL-17 exerts protective functions in colitis and targeting IL-17/M2-like macrophage axis may represent an important future therapeutic approach in the treatment of mucosal inflammatory diseases such as IBD. Here, IL17A is linked to inflammatory bowel disease.